Ultragenyx Reports Improved Q2 Financial Results Despite Loss Reduction

Ultragenyx Pharmaceutical Inc. (RARE) announced its financial performance for the second quarter, revealing a narrower net loss of $114.9 million. This loss equates to $1.17 per share, marking an improvement from the previous year's deficit of $131.6 million or $1.52 per share. During the same period, the company's revenue increased by 13.3%, reaching $166.5 million compared to $147.0 million in the previous year. Key financial indicators (GAAP): - Net loss: $114.9 million (previously $131.6 million) - Earnings per share: -$1.17 (previously -$1.52) - Revenue: $166.5 million (previously $147.0 million) Looking ahead, Ultragenyx projects full-year revenue between $640 million and $670 million. For further comments or feedback, contact: [email protected] Date: July 25, 2025, 14:49 ET In the U.S., recent highlights include housing market data and jobless claims figures. In Europe, attention centered on the European Central Bank's policy decision and sector trend surveys in manufacturing and services. Meanwhile, China's central bank made headlines with its latest interest rate decision.